All In MedTech

Device Trial Radar · NCT07257224

Post-market Clinical Follow-up Study of an Isotonic Saline Solution for the Relief of Nasal Congestion in Infants and Toddlers

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

83

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Oct 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Laboratoires Quinton International S.L.Not on our public-company list
Sponsor type
Industry
First posted
Dec 2, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 6 months, up to 48 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this observational post-market clinical follow-up study is to evaluate the safety and performance of the CE-marked nasal spray for the relief of nasal congestion in infants and toddlers aged 6 to 48 months at day 5 post-enrollment. Enrollment does not require establishing a medical diagnosis; eligibility is based on guardian-reported nasal congestion consistent with lay use of the device. Participants will be: * Evaluated by a healthcare professional for eligibility. * Receive treatment with the CE-marked nasal spray according to its Instructions for Use, for up to 14 days. * Have their legal guardians report symptom severity and improvement using standardized scales (Visual Analog Scale) during follow-up visits on Day 2, Day 5, and Day 14 and device usability on Day 14. This study does not include a comparison group and reflects real-world use of the device in routine pediatric care.

Conditions

  • Nasal Congestion
  • Common Cold
  • Allergic Rhinitis
  • Rhinosinusitis
  • Flu Symptom

Interventions

  • Quinton Medical Nasal Health Baby®Device

    CE-marked Class IIa isotonic seawater nasal spray intended for nasal hygiene and relief of nasal congestion in infants and toddlers. In this study, the device will be administered according to its Instructions for Use, up to 6 applications per day, for a maximum of 14 days. Participants will be evaluated at Day 2, Day 5, and Day 14 for symptom relief, nasal discharge clearance, breathing improvement, sleep quality, and safety outcomes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety - Treatment-related AEs and SAEs at Day 5 Performance - Improvement in nasal congestion improvement indicators at Day 5Time frame: Baseline to Day 5
  2. Functioning - Symptom improvement at Day 5Time frame: Baseline to Day 5

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Clínica Uner

    Alicante, Spain

  • Nombre de Mujer

    Alicante, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.